Development of target-specific treatments in multiple myeloma-Reference-Cited by-同舟云学术

Development of target-specific treatments in multiple myeloma

Published:2010-07-07 Issue:1 Volume:151 Page:3-15
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Chanan-Khan Asher A.,Borrello Ivan,Lee Kelvin P.,Reece Donna E.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08262.x/fullpdf

Reference94 articles.

1. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions;Anderson;Experimental Hematology,2007

2. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM);Anderson;Journal of Clinical Oncology (ASCO Meeting Abstracts),2008

3. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients;Badros;Journal of Clinical Oncology,2005

4. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma;Badros;Clinical Cancer Research,2009a

5. Tanespimycin + bortezomib in relapsed/refractory myeloma patients: results from the TIME-2 study;Badros;Blood (ASH Annual Meeting Abstracts),2009b

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world;Antibody Therapeutics;2023-04

2. Impact of mitochondrial DNA mutations in multiple myeloma;Blood Cancer Journal;2020-05

3. Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma;Oncotarget;2017-11-27

4. Reverting p53 activation after recovery of cellular stress to resume with cell cycle progression;Cellular Signalling;2017-05

5. Emerging antibodies for the treatment of multiple myeloma;Expert Opinion on Emerging Drugs;2016-04-02